241 related articles for article (PubMed ID: 32236967)
1. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
[TBL] [Abstract][Full Text] [Related]
2. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status.
Tessier-Cloutier B; Kortekaas KE; Thompson E; Pors J; Chen J; Ho J; Prentice LM; McConechy MK; Chow C; Proctor L; McAlpine JN; Huntsman DG; Gilks CB; Bosse T; Hoang LN
Mod Pathol; 2020 Aug; 33(8):1595-1605. PubMed ID: 32203095
[TBL] [Abstract][Full Text] [Related]
3. p53 Immunohistochemical Patterns in HPV-Independent Squamous Cell Carcinomas of the Vulva and the Associated Skin Lesions: A Study of 779 Cases.
Rakislova N; Alemany L; Clavero O; Saco A; Torné A; Del Pino M; Munmany M; Rodrigo-Calvo MT; Guerrero J; Marimon L; Vega N; Quirós B; Lloveras B; Ribera-Cortada I; Alejo M; Pawlita M; Quint W; de Sanjose S; Ordi J; Vvap Study Group
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138328
[TBL] [Abstract][Full Text] [Related]
4. Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
Xing D; Fadare O
Semin Diagn Pathol; 2021 Jan; 38(1):50-61. PubMed ID: 33032902
[TBL] [Abstract][Full Text] [Related]
5. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
Kortekaas KE; Bastiaannet E; van Doorn HC; de Vos van Steenwijk PJ; Ewing-Graham PC; Creutzberg CL; Akdeniz K; Nooij LS; van der Burg SH; Bosse T; van Poelgeest MIE
Gynecol Oncol; 2020 Dec; 159(3):649-656. PubMed ID: 32972785
[TBL] [Abstract][Full Text] [Related]
6. Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach.
Yang H; Almadani N; Thompson EF; Tessier-Cloutier B; Chen J; Ho J; Senz J; McConechy MK; Chow C; Ta M; Cheng A; Karnezis A; Huvila J; McAlpine JN; Gilks B; Jamieson A; Hoang LN
Mod Pathol; 2023 Jun; 36(6):100145. PubMed ID: 36828360
[TBL] [Abstract][Full Text] [Related]
7. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.
Dongre HN; Elnour R; Tornaas S; Fromreide S; Thomsen LCV; Kolseth IBM; Nginamau ES; Johannessen AC; Vintermyr OK; Costea DE; Bjørge L
Acta Obstet Gynecol Scand; 2024 Jan; 103(1):165-175. PubMed ID: 37840151
[TBL] [Abstract][Full Text] [Related]
9. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
Kashofer K; Regauer S
Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome.
Tessier-Cloutier B; Pors J; Thompson E; Ho J; Prentice L; McConechy M; Aguirre-Hernandez R; Miller R; Leung S; Proctor L; McAlpine JN; Huntsman DG; Gilks CB; Hoang LN
Mod Pathol; 2021 Feb; 34(2):508-518. PubMed ID: 32792599
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
[TBL] [Abstract][Full Text] [Related]
12. Time series analysis of TP53 gene mutations in recurrent HPV-negative vulvar squamous cell carcinoma.
Regauer S; Kashofer K; Reich O
Mod Pathol; 2019 Mar; 32(3):415-422. PubMed ID: 30291345
[TBL] [Abstract][Full Text] [Related]
13. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
[TBL] [Abstract][Full Text] [Related]
14. Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma.
Pinto AP; Miron A; Yassin Y; Monte N; Woo TY; Mehra KK; Medeiros F; Crum CP
Mod Pathol; 2010 Mar; 23(3):404-12. PubMed ID: 20062014
[TBL] [Abstract][Full Text] [Related]
15. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
[TBL] [Abstract][Full Text] [Related]
16. p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases.
Cheng AS; Karnezis AN; Jordan S; Singh N; McAlpine JN; Gilks CB
Int J Gynecol Pathol; 2016 Jul; 35(4):385-93. PubMed ID: 26630231
[TBL] [Abstract][Full Text] [Related]
17. Role of TP53 mutations in vulvar carcinomas.
Choschzick M; Hantaredja W; Tennstedt P; Gieseking F; Wölber L; Simon R
Int J Gynecol Pathol; 2011 Sep; 30(5):497-504. PubMed ID: 21804386
[TBL] [Abstract][Full Text] [Related]
18. Utilization of p53 and p16 Immunohistochemistry in the Classification of Human Papillomavirus-Associated, p53 Wild-Type, and p53 Abnormal Oral Epithelial Dysplasia.
Novack R; Chapman E; Gao J; Horst B; Hoang LN; Ng TL; Ko YCK
Mod Pathol; 2023 Dec; 36(12):100348. PubMed ID: 37820765
[TBL] [Abstract][Full Text] [Related]
19. Somatic Mutation Profiling in Premalignant Lesions of Vulvar Squamous Cell Carcinoma.
Zięba S; Pouwer AW; Kowalik A; Zalewski K; Rusetska N; Bakuła-Zalewska E; Kopczyński J; Pijnenborg JMA; de Hullu JA; Kowalewska M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664330
[TBL] [Abstract][Full Text] [Related]
20. p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations.
Sung YN; Kim D; Kim J
Diagn Pathol; 2022 Dec; 17(1):92. PubMed ID: 36471402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
